See also
ˇ Show More
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
You have visited 10 password protected pages for free. Others contain data covered by
.
Sign Up Now to get full access to whole website and cut out all advertisements.
Pfizer Inc., Consolidated Statement of Comprehensive Income
USD $ in millions
| 12 months ended | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
|---|---|---|---|---|---|---|
![]() |
Net income | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Currency translation adjustment and other | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Derivative financial instruments | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Available-for-sale securities | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Net unrealized gains (losses) | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Actuarial gains (losses) | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Prior service (costs) credits and other | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Benefit plans | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Other comprehensive income (loss) attributable to noncontrolling interests | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Other comprehensive income (loss) | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Comprehensive income (loss) | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Comprehensive income (loss) attributable to noncontrolling interests | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Comprehensive income (loss) attributable to Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
| Item | Description | The company |
|---|---|---|
| Currency translation adjustment and other | Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity. | Pfizer Inc.'s currency translation adjustment and other declined from 2009 to 2010 but then slightly increased from 2010 to 2011. |
| Derivative financial instruments | Net of tax effect change in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges, after taxes, that is attributable to the parent entity. A cash flow hedge is a hedge of the exposure to variability in the cash flows of a recognized asset or liability or a forecasted transaction that is attributable to a particular risk. The change includes an entity's share of an equity investee's increase (decrease) in deferred hedging gains or losses. | Pfizer Inc.'s derivative financial instruments declined from 2009 to 2010 but then slightly increased from 2010 to 2011. |
| Available-for-sale securities | Gross appreciation or the gross loss in value of the total unsold securities at the end of an accounting period, after tax, attributable to the parent entity. | Pfizer Inc.'s available-for-sale securities declined from 2009 to 2010 but then slightly increased from 2010 to 2011. |
| Benefit plans | Net changes to accumulated comprehensive income during the period related to benefit plans, after tax, attributable to the parent entity. | Pfizer Inc.'s benefit plans declined from 2009 to 2010 and from 2010 to 2011. |
| Comprehensive income (loss) attributable to Pfizer Inc. | The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. | Pfizer Inc.'s comprehensive income (loss) attributable to Pfizer Inc. declined from 2009 to 2010 but then increased from 2010 to 2011 not reaching 2009 level. |
May 19, 2012